Author

Paradise Madlala

Observed names: Madlala, P, Madlala, Paradise, P. Madlala, P. Z. Madlala

Observed institutions: Ragon Institute of MGH, MIT and Harvard, Hospital Clínico San Carlos, Africa Health Research Institute, University College London, University of KwaZulu-Natal, KU Leuven

ORCID: 0000-0003-0641-1452

Observed ORCID: 0000-0003-0641-1452

OpenAlex ID: A5024419639

BET-independent MLV-based Vectors Target Away From Promoters and Regulatory Elements

2014 · Sara El Ashkar, Jan De Rijck, et al. · Molecular Therapy — Nucleic Acids · 48

PDF

HIV-1 Integrase Variants Retarget Viral Integration and Are Associated with Disease Progression in a Chronic Infection Cohort

2014 · Jonas Demeulemeester, Sofie Vets, et al. · Cell Host & Microbe · 43

PDF

Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression

2011 · Paradise Madlala, Rik Gijsbers, et al. · AIDS · 27

8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19-22 July 2015, Vancouver, Canada

2015 · Pate, KM, Pohlmeyer, C, et al. · Journal of the International AIDS Society · 16

PDF

Association of Polymorphisms in the Regulatory Region of the Cyclophilin a Gene (PPIA) with Gene Expression and HIV/AIDS Disease Progression

2016 · Paradise Madlala, Ravesh Singh, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 14

Specific quantification of inducible HIV-1 reservoir by RT-LAMP

2024 · Tanvir Hossain, Cynthia Lungu, et al. · Communications Medicine · 13

Genetic variation of the HIV-1 subtype C transmitted/founder viruses long terminal repeat elements and the impact on transcription activation potential and clinical disease outcomes

2023 · Paradise Madlala, Zakithi Mkhize, et al. · PLoS Pathogens · 13

Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis

2024 · Paul O. Odeniran, Paradise Madlala, et al. · Cancers · 10

Herbal formulations, Product Nkabinde and Gnidia sericocephala, exhibit potent in vitro activity against HIV-1 infection

2025 · Khanyisile Mngomezulu, Paradise Madlala, et al. · Frontiers in Pharmacology · 5

PDF

Integrative genomic analyses combined with molecular dynamics simulations reveal the impact of deleterious mutations of Bcl-2 gene on the apoptotic machinery and implications in carcinogenesis

2025 · Ghazi Elamin, Zhichao Zhang, et al. · Frontiers in Genetics · 3

PDF

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

2023 · David M. MacDonald, Sarah Samorodnitsky, et al. · Scientific Reports · 3

PDF

Vulnerable targets in HIV-1 Pol for attenuation-based vaccine design

2020 · Doty B.A. Ojwach, Paradise Madlala, et al. · Virology · 3

Analysis of ex vivo HIV-1 infection in a controller-discordant couple

2018 · Paradise Madlala, Paulien Van de Velde, et al. · Journal of Virus Eradication · 3

PDF

Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal

2024 · Shreyal Maikoo, Robert-Jan Palstra, et al. · Journal of Virus Eradication · 2

IBA-1+CD68+ Germinal Center Macrophages Harbor Proviral and Inducible Clade C HIV Reservoirs in ART-Suppressed Human Lymph Nodes

2026 · Merantha Moodley, Tanvir Hossain, et al. · Research Square · 1

PDF

SQuHIVLa: A novel assay for Specific Quantification of inducible HIV-1 reservoir by LAMP

2023 · Tanvir Hossain, Cynthia Lungu, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1

PDF

Natural Product-Derived Disruption of the HIV-1 Integrase–LEDGF/p75 Complex: Molecular Insights into the Inhibitory Potential of Guanipiperazine B

2025 · Ibrahim Oluwatobi Kehinde, Paradise Madlala, et al. · Journal of Computational Biophysics and Chemistry

HIV-1 subtype C LTR Sp1IIIT5A mutant enhances transcription activity and Sp1 binding affinity

2025 · Nomcebo Msthali, Ibrahim Kehinde, et al. · bioRxiv (Cold Spring Harbor Laboratory)

PDF

Development of a latency model based on HIV-1 subtype C to study how long terminal repeat genetic variation impacts viral persistence and latency reversal

2024 · Shreyal Maikoo, Robert-Jan Palstra, et al. · bioRxiv (Cold Spring Harbor Laboratory)

PP 5.6 – 00183 Combination of traditional medicine product (SDK-2) with TNF-α synergistically reactivate latent HIV-1 subtype C in vitro

2022 · K. Mngomezulu, P. Madlala, et al. · Journal of Virus Eradication

PDF

PP 3.7 – 00128 Genetic variation of the HIV-1 subtype C transmitted/founder viruses long terminal repeat elements and the impact on transcription activation potential and clinical disease outcomes

2022 · P. Madlala, S. Khathi, et al. · Journal of Virus Eradication

PDF

PP 3.14 – 00190 Ex vivo response to latency reversal agents of CD4+ T cell subsets and monocyte derived HIV-1 subtype C LTR from individuals on suppressive cART

2022 · K. Gopee, T. Ndung'u, et al. · Journal of Virus Eradication

PDF

PP 1.36 – 00182 Effect of HIV-1C Transmitted/Founder Viruses 5′LTRand tat Genetic Variation on Viral Reservoir Size and Latency Reversal Potential

2022 · Shreyal Maikoo, Thumbi Ndung'u, et al. · Journal of Virus Eradication

PDF

Bone marrow stromal antigen 2 (BST-2) genetic variants influence expression levels and disease outcome in HIV-1 chronically infected patients

2022 · Hlelolwenkosi Mlimi, Kewreshini K. Naidoo, et al. · Retrovirology

PDF

Bone marrow stromal antigen 2 (BST-2) genetic variants influence expression levels and disease outcome in HIV-1 chronically infected patients

2021 · Hlelolwenkosi Mlimi, Kewreshini K. Naidoo, et al. · Research Square

PDF

Works count: 35

Citation count: 205

H-index: 8

I10-index: 8